Milone, Michael C.

Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia

Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine

CAR-T cell therapy researchAcute Lymphoblastic Leukemia research

Cited by 3,509

Car t cell immunotherapy for human cancer

June, C. H., O’Connor, R. S., Kawalekar, O. U., Ghassemi, S., & Milone, M. C. (2018) · Science

CAR-T cell therapy researchImmunotherapy and Immune Responses

Cited by 3,207

Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia

Porter, D. L., Hwang, W.-T., Frey, N. V., Lacey, S. F., Shaw, P. A., Loren, A. W., Bagg, A., Marcucci, K. T., Shen, A., Gonzalez, V., et al. (2015) · Science Translational Medicine

CAR-T cell therapy researchChronic Lymphocytic Leukemia Research

Cited by 1,729

Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In Vivo

Milone, M. C., Fish, J. D., Carpenito, C., Carroll, R. G., Binder, G. K., Teachey, D., Samanta, M., Lakhal, M., Gloss, B., Danet-Desnoyers, G., et al. (2009) · Molecular Therapy

CAR-T cell therapy researchImmunotherapy and Immune Responses

Cited by 1,197

Clinical use of lentiviral vectors

Milone, M. C., & O’Doherty, U. (2018) · Leukemia

Virus-based gene therapy researchCAR-T cell therapy research

Cited by 930

B cell maturation antigen–specific CAR T cells are clinically active in multiple myeloma

Cohen, A. D., Garfall, A. L., Stadtmauer, E. A., Melenhorst, J. J., Lacey, S. F., Lancaster, E., Vogl, D. T., Weiss, B. M., Dengel, K., Nelson, A., et al. (2019) · Journal of Clinical Investigation

CAR-T cell therapy researchMultiple Myeloma Research and Treatments

Cited by 778

An introduction to chimeric antigen receptor (CAR) T‐cell immunotherapy for human cancer

Feins, S., Kong, W., Williams, E. F., Milone, M. C., & Fraietta, J. A. (2019) · American Journal of Hematology

CAR-T cell therapy researchImmunotherapy and Immune Responses

Cited by 614

Targeted inhibition of tumor-specific glutaminase diminishes cell-autonomous tumorigenesis

Xiang, Y., Stine, Z. E., Xia, J., Lu, Y., O’Connor, R. S., Altman, B. J., Hsieh, A. L., Gouw, A. M., Thomas, A. G., Gao, P., et al. (2015) · Journal of Clinical Investigation

Cancer, Hypoxia, and MetabolismAmino Acid Enzymes and Metabolism

Cited by 409

Reducing Ex Vivo Culture Improves the Antileukemic Activity of Chimeric Antigen Receptor (CAR) T Cells

Ghassemi, S., Nunez-Cruz, S., O'Connor, R. S., Fraietta, J. A., Patel, P. R., Scholler, J., Barrett, D. M., Lundh, S. M., Davis, M. M., Bedoya, F., et al. (2018) · Cancer Immunology Research

CAR-T cell therapy researchImmunotherapy and Immune Responses

Cited by 312

Engineering Artificial Antigen-presenting Cells to Express a Diverse Array of Co-stimulatory Molecules

Suhoski, M. M., Golovina, T. N., Aqui, N. A., Tai, V. C., Varela-Rohena, A., Milone, M. C., Carroll, R. G., Riley, J. L., & June, C. H. (2007) · Molecular Therapy

Immunotherapy and Immune ResponsesVirus-based gene therapy research

Cited by 266

Results of ASERTAA, a Randomized Prospective Crossover Pharmacogenetic Study of Immediate-Release Versus Extended-Release Tacrolimus in African American Kidney Transplant Recipients

Trofe-Clark, J., Brennan, D. C., West-Thielke, P., Milone, M. C., Lim, M. A., Neubauer, R., Nigro, V., & Bloom, R. D. (2018) · American Journal of Kidney Diseases

Renal Transplantation Outcomes and TreatmentsPharmacogenetics and Drug Metabolism

Cited by 93

Anti-BCMA/CD19 CAR T Cells with Early Immunomodulatory Maintenance for Multiple Myeloma Responding to Initial or Later-Line Therapy

Garfall, A. L., Cohen, A. D., Susanibar-Adaniya, S. P., Hwang, W.-T., Vogl, D. T., Waxman, A. J., Lacey, S. F., Gonzalez, V. E., Fraietta, J. A., Gupta, M., et al. (2023) · Blood Cancer Discovery

CAR-T cell therapy researchMultiple Myeloma Research and Treatments

Cited by 83

Recovery of humoral immunity in patients with durable complete responses following chimeric antigen receptor modified t cells directed against CD19 (CTL019).

Schuster, S. J., Svoboda, J., Nasta, S., Chong, E. A., Porter, D. L., Landsburg, D. J., Mato, A. R., Bhoj, V. G., Milone, M., Lacey, S. F., et al. (2016) · Journal of Clinical Oncology

CAR-T cell therapy researchT-cell and B-cell Immunology

Cited by 10